Bill > HB2157

This bill expands the scope of practice for pharmacists in Kansas by allowing them to initiate therapy for COVID-19 through a statewide protocol, similar to existing protocols for influenza, strep throat, and urinary tract infections. The collaborative drug therapy management advisory committee will be responsible for developing detailed guidelines for this new protocol, which will specify the medications that can be used, required pharmacist training, documentation requirements, patient assessment tools, and communication protocols with patients' primary care providers. The bill also maintains the board's authority to deny, revoke, or suspend a pharmacist's license if they fail to adhere to the established protocols. This change represents an expansion of pharmacists' clinical responsibilities, potentially increasing access to COVID-19 testing and treatment in settings like pharmacies, and providing an additional healthcare service point during and after the pandemic.

Health and Social Services

Health and Human Services (H)

https://kslegislature.gov/li/b2025_26/measures/hb2157/